Skip to content

ACell, Inc. is now owned by Integra LifeSciences. View details

Clinical Applications



ACell’s wound management products include Cytal® Wound Matrix (sheets) and MicroMatrix® (particulate). Comprised of ACell’s core MatriStem UBM™ technology, the devices are ideal for use in a variety of acute and chronic wounds. The devices are minimally processed, maintain an intact epithelial basement membrane, and mitigate the inflammatory response while facilitating remodeling of functional tissue1.


Traumatic Wounds

MicroMatrix and Cytal Wound Matrix are available in various configurations to offer surgeons more options when managing traumatic injuries.  The products are easy to use, and are highly conformable in irregular and large wounds.

Traumatic injuries often have significant soft tissue loss.  Cytal Wound Matrix and MicroMatrix have successfully been used for traumatic wounds that are unable to obtain flap or graft coverage26.  The products have also been used to facilitate the remodeling of site-appropriate, functional tissue1 and manage wounds to full closure without the use of autologous skin grafts 18.


Necrotizing Soft Tissue Infections

Necrotizing soft tissue infections (NSTIs) occur when certain types of bacteria, viruses, or fungus get into a patient’s tissues, typically via a break in the skin. Once these microorganisms get into the tissues they reproduce, releasing a toxin into the body that destroys the surrounding tissue and muscle. NSTIs are associated with high mortality rates and require prompt treatment, which typically includes aggressive surgical removal of the diseased tissue.

Many survivors experience dramatic tissue loss and/or amputations that may require major reconstructive and cosmetic surgery. MicroMatrix and Cytal Wound Matrix can facilitate the remodeling of functional tissue1 and relieve some of the complexities of typical reconstruction procedures after major soft tissue loss.


Diabetic Foot Ulcers

Diabetic foot ulcers (DFUs) are common, but when they fail to heal and become chronic, they impair the quality of life of the patient, and can lead to severe complications. ACell’s UBM technology has been shown to modulate the immune response in wounds of diabetic patients. MicroMatrix and Cytal Wound Matrix may assist in diabetic wound healing by restoring an inflammatory state similar to that of non-diabetic patients27. ACell devices have also been shown to be a cost-effective alternative for the treatment of DFUs compared to other ECM devices28.

White Acell Logo
ACell Inc.
6640 Eli Whitney Drive
Columbia, MD 21046
High Contrast Mode